Immucell (ICCC) Income from Non-Controlling Interests (2020 - 2023)
Immucell's (ICCC) quarterly Income from Non-Controlling Interests came in at -$1.4 million in Q2 2023, down 101.67% on a YoY basis from $82.7 million in Q2 2022, and up 40.4% quarter-over-quarter from -$2.3 million in Q1 2023.
Powered by 
Analysis
Immucell (ICCC) Income from Non-Controlling Interests (2020 - 2023) Analysis & Trends
Immucell (ICCC) has reported Income from Non-Controlling Interests for 4 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2023.
- For the quarter ending Q2 2023, Income from Non-Controlling Interests fell 101.67% year-over-year to -$1.4 million; the trailing twelve-month figure through Jun 2023 stood at -$3.5 million (down 6991.29% YoY), and the FY2024 full-year result was $4619.0, down 11.53% from the prior year.
- Income from Non-Controlling Interests climbed to -$1.4 million in Q2 2023 per ICCC's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $832738.0 in Q4 2022 and bottomed at -$2.3 million in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged -$358931.6 across 4 years, with a median of -$322888.0 in 2020.
- The widest YoY moves for Income from Non-Controlling Interests: up 1023.29% in 2022, down 584.82% in 2022.
- Over 4 years, Income from Non-Controlling Interests stood at $188830.0 in 2020, then slumped by 60.74% to $74134.0 in 2021, then surged by 1023.29% to $832738.0 in 2022, then slumped by 265.68% to -$1.4 million in 2023.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$1.4 million, -$2.3 million, and $832738.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | - |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | - |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | - |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | - |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -1.38 Mn |
| Mar 31, 2023 | -2.32 Mn |
| Dec 31, 2022 | 832,738.00 |
| Sep 30, 2022 | -655,078.00 |
| Jun 30, 2022 | -684,148.00 |
| Mar 31, 2022 | 513,287.00 |
| Dec 31, 2021 | 74,134.00 |
| Sep 30, 2021 | 147,764.00 |
| Jun 30, 2021 | 141,113.00 |
| Mar 31, 2021 | -441,303.00 |
| Dec 31, 2020 | 188,830.00 |
| Sep 30, 2020 | -322,888.00 |
| Jun 30, 2020 | -765,793.00 |